Cecelia Health
PrivateLast Round
Series B
Aug 13, 2020
Total Funding Raised
$15.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Cecelia Health operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series B round in August 2020.
Cecelia Health is a healthcare technology company that operates a virtual specialty medical practice providing coaching and clinical support for individuals with chronic conditions.
Sector
Healthcare & Life Sciences
Verticals
Telemedicine, Patient Engagement, Healthcare Analytics
Business Model
B2B2C
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cecelia Health Comparables
Compare Cecelia Health with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vida Health | 87% | |
| Welldoc | 83% | |
| Form Health | 82% |
For institutional investors. Book with your work email.
Cecelia Health Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 13, 2020 | ||||
| VC Round | Sep 4, 2018 | ||||
| Series A | Aug 19, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cecelia Health Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Endo Investors | Series B |
| Boston Millennia Partners | Series B |
| SJF Ventures | Series A, VC Round |
| StartUp Health | VC Round |
| C&B Capital | VC Round |
| Rittenhouse Ventures | Series B |
| SustainVC | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Open roles increased to 150, 32% of headcount.
- Jul 20, 2026
Open roles increased to 150, 32% of headcount.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesNov 4, 2026
Payer Matrix, Cecelia Health, and Blue Genes Lab jointly launch PreciselyRx, an integrated medication management program that claims to deliver brand-name GLP-1 therapies at approximately half the cost of standard coverage, on Nov 4th '26.
For institutional investors. Book with your work email.
Cecelia Health Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cecelia Health's valuation, stock price, and market status.
Is Cecelia Health a public or private company?
Cecelia Health is a private company.
What is the current stock price of Cecelia Health?
Cecelia Health is a private company, so its shares have no public market price. Caplight tracks Cecelia Health's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cecelia Health worth (valuation)?
Valuation information for Cecelia Health is not publicly available.
Can I buy Cecelia Health stock?
Cecelia Health shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cecelia Health's last funding round?
Cecelia Health's most recent funding round was Series B on August 13, 2020.
Who are the main investors in Cecelia Health?
Key investors in Cecelia Health include Endo Investors, SJF Ventures, Rittenhouse Ventures.
Will Cecelia Health IPO soon?
No public IPO plans have been announced for Cecelia Health.
How can I track Cecelia Health secondary market activity?
Caplight tracks bids, offers, and trades in Cecelia Health's shares on secondary markets.